Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

Li Tan, Suman Rao, Samar Mowafy, Guangyan Du, Nathanael S. Gray, Deepak Gurbani, Ellen L. Weisberg, Douglas S. Jones, William D. Singer, Faviola M. Bernard, Annie Jenney, Atsushi Nonami, James D. Griffin, Douglas A. Lauffenburger, Kenneth D. Westover, Peter K. Sorger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound 5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of 5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.

Original languageEnglish
Pages (from-to)1320-1328
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume25
Issue number4
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Polypharmacology
Phosphotransferases
Neoplasms
Cells
Derivatives
Cell Line

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Tan, L., Rao, S., Mowafy, S., Du, G., Gray, N. S., Gurbani, D., ... Sorger, P. K. (2017). Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 25(4), 1320-1328. https://doi.org/10.1016/j.bmc.2016.11.034

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. / Tan, Li; Rao, Suman; Mowafy, Samar; Du, Guangyan; Gray, Nathanael S.; Gurbani, Deepak; Weisberg, Ellen L.; Jones, Douglas S.; Singer, William D.; Bernard, Faviola M.; Jenney, Annie; Nonami, Atsushi; Griffin, James D.; Lauffenburger, Douglas A.; Westover, Kenneth D.; Sorger, Peter K.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 4, 01.01.2017, p. 1320-1328.

Research output: Contribution to journalArticle

Tan, L, Rao, S, Mowafy, S, Du, G, Gray, NS, Gurbani, D, Weisberg, EL, Jones, DS, Singer, WD, Bernard, FM, Jenney, A, Nonami, A, Griffin, JD, Lauffenburger, DA, Westover, KD & Sorger, PK 2017, 'Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors', Bioorganic and Medicinal Chemistry, vol. 25, no. 4, pp. 1320-1328. https://doi.org/10.1016/j.bmc.2016.11.034
Tan, Li ; Rao, Suman ; Mowafy, Samar ; Du, Guangyan ; Gray, Nathanael S. ; Gurbani, Deepak ; Weisberg, Ellen L. ; Jones, Douglas S. ; Singer, William D. ; Bernard, Faviola M. ; Jenney, Annie ; Nonami, Atsushi ; Griffin, James D. ; Lauffenburger, Douglas A. ; Westover, Kenneth D. ; Sorger, Peter K. / Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. In: Bioorganic and Medicinal Chemistry. 2017 ; Vol. 25, No. 4. pp. 1320-1328.
@article{046be37bf2f8467cbd398490bc1841a1,
title = "Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors",
abstract = "Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound 5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of 5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.",
author = "Li Tan and Suman Rao and Samar Mowafy and Guangyan Du and Gray, {Nathanael S.} and Deepak Gurbani and Weisberg, {Ellen L.} and Jones, {Douglas S.} and Singer, {William D.} and Bernard, {Faviola M.} and Annie Jenney and Atsushi Nonami and Griffin, {James D.} and Lauffenburger, {Douglas A.} and Westover, {Kenneth D.} and Sorger, {Peter K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.bmc.2016.11.034",
language = "English",
volume = "25",
pages = "1320--1328",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors

AU - Tan, Li

AU - Rao, Suman

AU - Mowafy, Samar

AU - Du, Guangyan

AU - Gray, Nathanael S.

AU - Gurbani, Deepak

AU - Weisberg, Ellen L.

AU - Jones, Douglas S.

AU - Singer, William D.

AU - Bernard, Faviola M.

AU - Jenney, Annie

AU - Nonami, Atsushi

AU - Griffin, James D.

AU - Lauffenburger, Douglas A.

AU - Westover, Kenneth D.

AU - Sorger, Peter K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound 5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of 5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.

AB - Targeted polypharmacology provides an efficient method of treating diseases such as cancer with complex, multigenic causes provided that compounds with advantageous activity profiles can be discovered. Novel covalent TAK1 inhibitors were validated in cellular contexts for their ability to inhibit the TAK1 kinase and for their polypharmacology. Several inhibitors phenocopied reported TAK1 inhibitor 5Z-7-oxozaenol with comparable efficacy and complementary kinase selectivity profiles. Compound 5 exhibited the greatest potency in RAS-mutated and wild-type RAS cell lines from various cancer types. A biotinylated derivative of 5, 27, was used to verify TAK1 binding in cells. The newly described inhibitors constitute useful tools for further development of multi-targeting TAK1-centered inhibitors for cancer and other diseases.

UR - http://www.scopus.com/inward/record.url?scp=85009355270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009355270&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2016.11.034

DO - 10.1016/j.bmc.2016.11.034

M3 - Article

C2 - 28038940

AN - SCOPUS:85009355270

VL - 25

SP - 1320

EP - 1328

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 4

ER -